Congress carves out small biotech from Medicare drug price negotiations

What it does

This bill exempts drugs made by small biotech companies from Medicare's drug price negotiation program, starting in 2029. A company qualifies if it has 5 or fewer drugs on the market, invests a rising percentage of revenue in R&D (30–70% depending on drug count), and is not foreign-owned. Once acquired by a larger company, the exemption ends.

Why we flagged it

The bill creates a narrow exemption from Medicare price negotiation for a specific class of drug manufacturers, protecting their pricing power at public expense. This is a direct subsidy of manufacturer revenue through exemption from cost-control mechanisms.

What the text implies

• The R&D investment threshold scales with drug count (30–70% of net revenue), creating an incentive for small biotech firms to concentrate their portfolio and maximize R&D spending to qualify, potentially distorting investment decisions away from market need.
• The acquisition clause (clause iii) creates a cliff: once a qualifying small biotech is bought by a larger firm, all its drugs lose exemption immediately. This may depress acquisition valuations for small biotech firms or incentivize them to remain independent, affecting M&A dynamics.
• The exemption applies indefinitely to qualifying drugs, not just for a limited period. A drug approved in 2029 under this exemption could remain outside negotiation for decades, locking in higher prices for the life of the patent.
• The bill requires annual certification of R&D spending but does not define how R&D is calculated under GAAP, creating potential for aggressive accounting and disputes with CMS over qualification status.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary people and Medicare beneficiaries lose access to negotiated lower drug prices for medications made by qualifying small biotech firms. The exemption preserves manufacturers' ability to set prices without negotiation, shifting costs to patients and the federal program.

Who stands to gain

• small biotech manufacturers (5 or fewer drugs)
• biotech sector (R&D-intensive firms)

Named in the bill

Medicare, Social Security Act, Secretary of Health and Human Services, small biotech manufacturers, qualifying single source drugs

Where it stands

4 cosponsors: 3 Republicans, 1 Democrats.

• Jun 4, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jun 4, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 5 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,970,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

August Pfluger, the sponsor, reported $1,070,325 in PAC receipts in the 2026 cycle.

• Acadia Pharmaceuticals — $1,290,000 on 2 filings
• Exelixis Inc. — $560,000 on 1 filing
• Exelixis, Inc. — $120,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.